The American Journal of Managed Care

Study: Host Immune Classifier Test Predicts ICI Response in Advanced NSCLC

Patients treated with immune checkpoint inhibitors had significantly different survival rates based on the test, regardless of PD ligand 1 classification. A blood-based proteomic test can help ...
ascopubs.org

Real-world healthcare resource utilization amongst non-small cell lung cancer (NSCLC) patients tested with a host immune classifier (HIC).

Impact of a pathologist-driven molecular testing protocol on veterans with non-small cell lung cancer. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not ...
Business Wire

Biodesix to Showcase New Data on Patient Immune Profiling from Multiple Studies at World Lung Conference

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that three abstracts from multiple ...
ascopubs.org

Real-world healthcare costs amongst non-small cell lung cancer (NSCLC) patients tested with a host immune classifier (HIC).

Prevalence of STK11, KEAP1, and KRAS mutations/co-mutations and associated clinical outcomes for patients newly diagnosed with metastatic non-small cell lung cancer. This is an ASCO Meeting Abstract ...
Nasdaq

Biodesix to Showcase New Data on Patient Immune Profiling from Multiple Studies at World Lung Conference

Important New Findings Validate Testing Strategies That Support Decision Making for Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) MA08.03: Immunotherapy alone or with chemotherapy in ...